Innovative Research Pipeline


Glenmark’s innovative pipeline is focused on three core therapeutic areas: oncology, immunology and pain. Our pipeline demonstrates our efforts to solve some of medicine’s most difficult challenges and discover molecular entities that may one day have a major impact on how people live. With hundreds of scientists dedicated to new chemical entity (NCE) research and new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With NBEs, and NCEs various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.

Glenmark thanks all the volunteers who participate in our clinical trials. They are vital to our research advancement. To learn more about our clinical trials, please visit www.clinicaltrials.gov.

Molecule
Potential Indication(s)
MoA/Class
Pre-CLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVAL
ONCOLOGY
GBR 1302
HER2 positive cancers such as breast cancer
HER2xCD3
(BEAT® bsAb)
HER2 positive cancers such as breast cancer
HER2xCD3
(BEAT® bsAb)
PHASE 1
GBR 1342
Multiple myeloma
EGFRxCD3
(BEAT® bsAb)
Multiple myeloma
EGFRxCD3
(BEAT® bsAb)
Phase 1
TBD
TBD
MAP4K1 inhibitor
TBD
MAP4K1 inhibitor
Pre-CLINICAL
IMMUNOLOGY
GBR 830
Atopic dermatitis
OX40 Antagonist (mAb)
Atopic dermatitis
OX40 Antagonist (mAb)
PHASE 2
PAIN
GRC 27864*
Osteoarthritis pain
mPGES-1 inhibitor
Osteoarthritis pain
mPGES-1 inhibitor
PHASE 2
GRC 17536*
Neuropathic pain
TRPA 1 antagonist
Neuropathic pain
TRPA 1 antagonist
PHASE 2
Pipeline as of August 1, 2019
*Ex-US studies